Figure 3
Survival with BC in the preimatinib and imatinib eras. Most long-term survivors (72%) are transplant recipients. German CML Study Group experience (1983-2011). Data are from the German CML-studies I to IV.42
Survival with BC in the preimatinib and imatinib eras. Most long-term survivors (72%) are transplant recipients. German CML Study Group experience (1983-2011). Data are from the German CML-studies I to IV.42
